Titlebook: Safety and efficacy of radiopharmaceuticals; Knud Kristensen,Elisabeth N?rbygaard Book 1984 Martinus Nijhoff Publishers, Boston 1984 clini

Glycogen

Drug-Radiopharmaceutical Interactions and Other Possible Modifications in Radiopharmaceutical Biodisawareness of . alterations in radiopharmaceutical biodistribution (1). These unexpected changes in the biodistribution of the tracer may reduce the diagnostic value of nuclear medicine imaging or, worse, give rise to misleading results or to the necessity of revising dosimetric calculations.

易怒

Introductions available. After the design of a new chemical compound, methods are developed for its description, identification and determination. A stable pharmaceutical form and a production system are developed and a clinical trial through phase 1 to 3 is carried out. At a later stage, phase 4, including a c

GUILT

Structure Distribution Relationship in the Design of Tc-99m Radiopharmaceuticals-Brown and Fraser (1) advanced the idea that for any drug, Biological Response (activity), BR= f (S) where f (S) is a function of chemical structure. They suggested that it should be possible to develop a mathematical formulation of QSAR by making changes in the chemical structure and relating these

Inscrutable

Physical/Chemical Descriptionhe group named “radiopharmaceuticals” is quite inhomogeneous in the chemical and physical properties of its individuals it is useful to explain why and when the particular methods are being used, i.e. to explain the methodical approach.

江湖郎中

gerontocracy

迅速成長

Preclinical Studies — Radiopharmacology And Toxicologytic effect is achieved as the result of radiation induced damage. Diagnostic reagents tend to follow well defined metabolic pathways in the body or they are passively transported unchanged as the result of physiological activity and the movement of body fluids. In either case the biodistribution ref

agnostic

Human Pharmacology — Pharmacokineticsin vitro and on animals. From the results on animals, physicians try to extrapolate to humans, healthy volunteers and patients. They compare the new radiopharmaceuticals to well-known tracers and, in some way, to other diagnostic or therapeutic methods, for instance, new brain radiopharmaceuticals,

不在灌木叢中

蜈蚣

Clinical Trials of Radiopharmaceuticalsit of the patient (1). Accordingly radiopharmaceuticals whether intended for scientific investigational purposes or for diagnostic or therapeutic purposes are covered by the definition and subject to the professional principles underlying the development of drugs in general — including the clinical